Tumor necrosis factor-alpha: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett |
||
| Line 4: | Line 4: | ||
==Tumor necrosis factor inhibitors== | ==Tumor necrosis factor inhibitors== | ||
* TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of TNF-alpha.<ref>{{MedMaster|Etanercept}}</ref> | * TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of TNF-alpha.<ref>{{MedMaster|Etanercept}}</ref> | ||
* Infliximab is a chimeric monoclonal antibody that blocks the action of TNF-alpha by binding to it.<ref>{{MedMaster|Infliximab}}</ref> | * Infliximab (pronounced in flix' i mab)is a chimeric monoclonal antibody that blocks the action of TNF-alpha by binding to it.<ref>{{MedMaster|Infliximab}}</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 14:20, 1 September 2008
In medicine, tumor necrosis factor-alpha is a "serum glycoprotein produced by activated macrophages and other mammalian mononuclear leukocytes. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to tnf-beta (lymphotoxin), but they share TNF receptors.[1]
Tumor necrosis factor inhibitors
- TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of TNF-alpha.[2]
- Infliximab (pronounced in flix' i mab)is a chimeric monoclonal antibody that blocks the action of TNF-alpha by binding to it.[3]
References
- ↑ Anonymous (2024), Tumor necrosis factor-alpha (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Template:MedMaster
- ↑ Template:MedMaster